Response to DLT for recurrent ALL after BMT: EBMT-95 survey
Treatment . | No. of patients in CR/patients studied . | Survival time, d . |
|---|---|---|
| No chemotherapy | 1/8 | 417 |
| Chemotherapy with CR | 15/20 | 55, 59, 110, 122+, 132, 158, 185, 192, 241, 361, 464, 701+, 721, 1053, 1197 |
| Chemotherapy without CR | 2/12 | 367, 371+ |
Treatment . | No. of patients in CR/patients studied . | Survival time, d . |
|---|---|---|
| No chemotherapy | 1/8 | 417 |
| Chemotherapy with CR | 15/20 | 55, 59, 110, 122+, 132, 158, 185, 192, 241, 361, 464, 701+, 721, 1053, 1197 |
| Chemotherapy without CR | 2/12 | 367, 371+ |
Following allogeneic SCT, 40 patients in the EBMT-95 cohort were treated with DLT. One group of 8 patients received no chemotherapy prior to DLT; only one of these individuals achieved complete remission. Following chemotherapy, 20 patients entered complete remission; in 5 patients ALL had relapsed prior to DLT. Their survival times after DLT revealed a broad time span, with most responses lasting more than 100 days. Of 12 patients who failed to achieve complete remission with chemotherapy, 2 benefited from DLT, achieving survival times of more than one year.